reviewTop 10% cited
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Cancer Letters · 2009 · Vol. 280(2) · pp. 233–241
Peter Atadja✉(Novartis (Switzerland))
Histone Deacetylase Inhibitors ResearchProtein Degradation and InhibitorsEpigenetics and DNA MethylationPanobinostatHistone deacetylaseAcetylationHistoneHistone deacetylase inhibitorCancer researchCancerMedicinePharmacologyBiology
MeSH terms
PanobinostatAcetylationAnimalsAntineoplastic AgentsCell SurvivalDrug Evaluation, PreclinicalHistone DeacetylasesHumansHydroxamic AcidsIndolesCell Line, TumorCell ProliferationHistone Deacetylase Inhibitors
Citations
414
FWCI
10.22
field-weighted impact
References
43
Percentile
99%
vs. same field & year
Citations per year
Cited by
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
European Journal of Medicinal Chemistry · 2017 · 603 citations
Indole: A privileged scaffold for the design of anti-cancer agents
European Journal of Medicinal Chemistry · 2019 · 482 citations
References
Anticancer activities of histone deacetylase inhibitors
Nature Reviews Drug Discovery · 2006 · 2,905 citations
Histone deacetylases and cancer
Oncogene · 2007 · 1,039 citations
Targeting HIF-1 for cancer therapy
Nature reviews. Cancer · 2003 · 6,642 citations
Cancer epigenomics: DNA methylomes and histone-modification maps
Nature Reviews Genetics · 2007 · 2,173 citations
The epigenetic progenitor origin of human cancer
Nature Reviews Genetics · 2005 · 1,846 citations
Chromatin Modifications and Their Function
Cell · 2007 · 10,677 citations
The Epigenomics of Cancer
Cell · 2007 · 4,415 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.